2Tipples GA,Ma MM,Fischer KP.Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo[J].Hepatology,1996,24:714-717.
3Guha C,Shah SJ,Ghosh SS,et al.Molecular therapies for viral hepatitis[J].Biol Drugs,2003,17:81-91.
4Ling R,Mutimer D,Ahmed M.Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine [J].Hepatology,1996,24:711-713.
5Pramoolsinsup C.Management of viral hepatitis B[J].J Gastroenterol Hepatol,2002,17(Suppl):S125-S145.
6von Weizsacker F,Kock J,Wieland S,et al.Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis[J].Hepatology,1999,30(1):308-315.
8Scaglioni P,Melegari M,Takahashi M,et al.Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents[J].Hepatology,1996,24(5):1010-1017.
9von Weizsacker F,Wieland S,Blum HE.Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein[J].Hepatology,1996,24(2):294-299.
10Scaglioni PP,Melegari M,Wands JR.Characterization of hepatitis B virus core mutants that inhibit viral replication[J].Virology,1994,205(1):112-120.
